Compare · BRTX vs CLBS
BRTX vs CLBS
Side-by-side comparison of BioRestorative Therapies Inc. (BRTX) and Caladrius Biosciences Inc. (CLBS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BRTX and CLBS operate in Managed Health Care (Health Care), so they compete in similar markets.
- CLBS is the larger of the two at $43.6M, about 4.2x BRTX ($10.3M).
- BRTX has hit the wire 3 times in the past 4 weeks while CLBS has been quiet.
- BRTX has more recent analyst coverage (1 ratings vs 0 for CLBS).
- Company
- BioRestorative Therapies Inc.
- Caladrius Biosciences Inc.
- Price
- $0.38-6.83%
- $6.45+1176.72%
- Market cap
- $10.3M
- $43.6M
- 1M return
- +63.76%
- -
- 1Y return
- -79.34%
- -
- Industry
- Managed Health Care
- Managed Health Care
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 3
- 0
- Recent ratings
- 1
- 0
BioRestorative Therapies Inc.
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100 that has completed Phase 1 clinical trials is a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate, which is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue (BAT). In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
Caladrius Biosciences Inc.
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Latest BRTX
- BioRestorative Therapies Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)
- BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data
- SEC Form 10-Q filed by BioRestorative Therapies Inc.
- BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals
- BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease
- BioRestorative Therapies Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 424B3 filed by BioRestorative Therapies Inc.
- BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform
- SEC Form EFFECT filed by BioRestorative Therapies Inc.
Latest CLBS
- SEC Form 4: Mazzo David J covered exercise/tax liability with 397 shares, decreasing direct ownership by 0.41% to 96,543 units
- SEC Form 4: Mazzo David J covered exercise/tax liability with 1,030 shares, decreasing direct ownership by 1% to 96,940 units
- SEC Form 4: Ruoslahti Erkki was granted 20,000 shares
- SEC Form 4: Klosk Steven M was granted 20,000 shares, increasing direct ownership by 198% to 30,090 units
- SEC Form 4: Henson Heidi was granted 20,000 shares
- SEC Form 4: Flowers Cynthia Louise was granted 20,000 shares, increasing direct ownership by 206% to 29,721 units
- SEC Form 4: Brown Gregory B was granted 20,000 shares, increasing direct ownership by 201% to 29,934 units
- SEC Form 4: Azab Mohammad was granted 20,000 shares, increasing direct ownership by 104% to 39,200 units
- SEC Form 4: Slack David W. was granted 24,000 shares and covered exercise/tax liability with 3,358 shares
- SEC Form 4: Mazzo David J was granted 60,000 shares and covered exercise/tax liability with 11,315 shares, increasing direct ownership by 99% to 97,970 units